Table II.
Perioperative characteristics and surgical strategy used for the initial treatment of patients with a hemiarthroplasty periprosthetic joint infection.
| Variable | Value |
|---|---|
| Mean preoperative serology, value (SD) | |
| Hgb, g/l | 103.45 (15.0) |
| WBC, g/l | 9.84 (4.12) |
| Creatinine, umol/l | 112.07 (91.4) |
| ESR, mm/hr | 73.42 (57.4) |
| CRP, mg/l | 55.63 (29.7) |
| Time to infection, n (%) | |
| ≤ 6 wks | 25 (56.8) |
| > 6 wks | 19 (43.2) |
| Type of surgery, n (%) | |
| DAIR | 26 (59.1) |
| Revision arthroplasty | 18 (40.9) |
| Single-stage revision hemiarthroplasty | 6 (13.6) |
| Single-stage revision to THA | 12 (27.3) |
| Surgery performed by arthroplasty surgeon, n (%) | 28 (63.6) |
| Microbiology, n (%) | |
| Gram-positive | 22 (50.0) |
| Gram-negative | 3 (6.8) |
| Polymicrobial | 11 (25.0) |
| No growth | 8 (18.2) |
ASA, American Society of Anesthesiologists; CCI, Charlson Comorbidity Index; SD, standard deviation; THA, total hip arthroplasty.